Literature DB >> 35303685

ScRNA-seq identified the metabolic reprogramming of human colonic immune cells in different locations and disease states.

Qiuchen Zhao1, Tong Zhang2, Hao Yang3.   

Abstract

Different regions and states of the human colon are likely to have a distinct influence on immune cell functions. Here we studied the immunometabolic mechanisms for spatial immune specialization and dysregulated immune response during ulcerative colitis at single-cell resolution. We revealed that the macrophages and CD8+ T cells in the lamina propria of the human colon possessed an effector phenotype and were more activated, while their lipid metabolism was suppressed compared with those in the epithelial. Also, IgA+ plasma cells accumulated in lamina propria of the sigmoid colon were identified to be more metabolically activated versus those in the cecum and transverse colon, and the improved metabolic activity was correlated with the expression of CD27. In addition to the immunometabolic reprogramming caused by spatial localization colon, we found dysregulated cellular metabolism was related to the impaired immune functions of macrophages and dendritic cells in patients with ulcerative colitis. The cluster of OSM+ inflammatory monocytes was also identified to play its role in resistance to anti-TNF treatment, and we explored targeted metabolic reactions that could reprogram them to a normal state. Altogether, this study revealed a landscape of metabolic reprogramming of human colonic immune cells in different locations and disease states, and offered new insights into treating ulcerative colitis by immunometabolic modulation.
Copyright © 2022 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Anti-TNF therapy Resistance; Human colon; Immunometabolic modulation; Inflammation; Single-cell immunometabolism; Spatial immune specialization; Ulcerative colitis

Mesh:

Substances:

Year:  2022        PMID: 35303685     DOI: 10.1016/j.bbrc.2022.03.034

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  1 in total

1.  BUB1 Is Identified as a Potential Therapeutic Target for Pancreatic Cancer Treatment.

Authors:  Ming Li; Xiaoyang Duan; Yajie Xiao; Meng Yuan; Zhikun Zhao; Xiaoli Cui; Dongfang Wu; Jian Shi
Journal:  Front Public Health       Date:  2022-06-13
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.